Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
FATE Fate Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: FATE
Price (delayed)
$1.04
Market cap
$119.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.64
Enterprise value
$158.16M
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture
Highlights
The debt has declined by 18% year-on-year and by 14% since the previous quarter
The gross profit has dropped by 79% year-on-year
FATE's revenue has dropped by 79% year-on-year
Key stats
What are the main financial stats of FATE
Market
Valuations
Earnings
Shares outstanding
114.6M
Market cap
$119.18M
Enterprise value
$158.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.37
Price to sales (P/S)
8.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.6
Revenue
$13.63M
Gross profit
$13.63M
Operating income
-$210.28M
Net income
-$186.26M
EBIT
-$186.26M
EBITDA
-$167.3M
Free cash flow
-$123.6M
Per share
Balance sheet
Liquidity
EPS
-$1.64
EPS diluted
-$1.64
Free cash flow per share
-$1.09
Book value per share
$2.8
Revenue per share
$0.12
TBVPS
$3.88
Total assets
$440.69M
Total liabilities
$121.97M
Debt
$85.27M
Equity
$318.73M
Working capital
$253.39M
Debt to equity
0.27
Current ratio
7.58
Quick ratio
7.6
Net debt/EBITDA
-0.23
Margins
Efficiency
Dividend
EBITDA margin
-1,227.3%
Gross margin
100%
Net margin
-1,366.5%
Operating margin
-1,542.6%
Return on assets
-36.6%
Return on equity
-49.5%
Return on invested capital
-37.6%
Return on capital employed
-46.3%
Return on sales
-1,366.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FATE stock price
How has the Fate Therapeutics stock price performed over time
Intraday
0.97%
1 week
-20.61%
1 month
13.09%
1 year
-73.33%
YTD
-36.97%
QTD
31.63%
Financial performance
How have Fate Therapeutics's revenue and profit performed over time
Revenue
$13.63M
Gross profit
$13.63M
Operating income
-$210.28M
Net income
-$186.26M
Gross margin
100%
Net margin
-1,366.5%
The gross profit has dropped by 79% year-on-year
FATE's revenue has dropped by 79% year-on-year
The net income has contracted by 16% YoY and by 4.5% from the previous quarter
FATE's operating income is down by 10% year-on-year and by 7% since the previous quarter
Price vs fundamentals
How does FATE's price correlate with its fundamentals
Growth
What is Fate Therapeutics's growth rate over time
Valuation
What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
0.37
P/S
8.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.6
FATE's price to book (P/B) is 93% lower than its 5-year quarterly average of 5.0 and 66% lower than its last 4 quarters average of 1.1
The company's equity fell by 13% YoY and by 12% QoQ
The stock's price to sales (P/S) is 89% less than its 5-year quarterly average of 81.1 and 82% less than its last 4 quarters average of 47.6
FATE's revenue has dropped by 79% year-on-year
Efficiency
How efficient is Fate Therapeutics business performance
The ROIC has contracted by 34% YoY and by 8% from the previous quarter
The ROE has contracted by 30% YoY and by 8% from the previous quarter
Fate Therapeutics's return on assets has decreased by 29% YoY and by 8% QoQ
FATE's return on sales is down by 3.1% since the previous quarter
Dividends
What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FATE.
Financial health
How did Fate Therapeutics financials performed over time
FATE's total assets is down by 13% year-on-year and by 11% since the previous quarter
FATE's current ratio is down by 11% YoY and by 9% from the previous quarter
The debt is 73% smaller than the equity
The debt has declined by 18% year-on-year and by 14% since the previous quarter
The company's equity fell by 13% YoY and by 12% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.